3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase NA
3
Phase 4
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Squamous Cell Carcinoma of Head and Neck
1
Salivary Gland Neoplasms
1
Recurrence
1
Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Head and Neck Neoplasms
1
Glioblastoma
1
Interventions
Brentuximab Vedotin
3
relmacabtagene autoleucel
2
fludarabine phosphate
2
fludarabine
2
Cytarabine
2
Bortezomib
2
Antilymphocyte Serum
2
xihuang
1
tocilizumab
1
tislelizumab
1
sofosbuvir-velpatasvir drug combination
1
sintilimab
1
rasburicase
1
ledipasvir
1
entecavir
1
apatinib
1
aflibercept
1
acalabrutinib
1
Urate Oxidase
1
Trabectedin
1
Thiotepa
1
Thalidomide
1
Tenofovir
1
Tamsulosin
1
Sofosbuvir
1
Sevoflurane
1
Rivaroxaban
1
Ribavirin
1
Radiotherapy
1
Radiosurgery
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Recurrence
×
Radiosurgery
×
Clear all
NCT05900908
2025-04-10
PATHWAyS
GT Medical Technologies, Inc.
Phase 4
Withdrawn